- Q4 2023 Medivir AB Earnings Call TranscriptFeb 15, 2024kr2.97 (+3.31%)Earnings
- Medivir AB to Discuss the Updated Data in Advanced Hepatocellular Carcinoma Call TranscriptJan 23, 2024
- Q3 2023 Medivir AB Earnings Call TranscriptOct 27, 2023kr5.73 (-10.26%)Earnings
- Q2 2023 Medivir AB Earnings Call TranscriptAug 18, 2023kr6.06 (-1.29%)Earnings
- Q1 2023 Medivir AB Earnings Call TranscriptApr 27, 2023kr6.11Earnings
- Q4 2022 Medivir AB Earnings Call TranscriptFeb 15, 2023kr7.05 (-3.37%)Earnings
- Medivir AB at Redeye Fight Cancer Day (Virtual) TranscriptJan 19, 2023
- Q3 2022 Medivir AB Earnings Call TranscriptNov 03, 2022kr6.61 (+0.75%)Earnings
- Q2 2022 Medivir AB Earnings Call TranscriptAug 19, 2022kr6.67 (+3.83%)Earnings
- Q1 2022 Medivir AB Earnings Call TranscriptApr 28, 2022kr6.54 (+1.01%)Earnings
- Q4 2021 Medivir AB Earnings Call TranscriptFeb 15, 2022kr6.84 (+1.21%)Earnings
- Q3 2021 Medivir AB Earnings Call TranscriptNov 03, 2021kr7.66 (+1.85%)Earnings
- Medivir AB to Discuss Update on the Progress and Plans for the MIV-818 Program Call TranscriptSep 16, 2021
- Q2 2021 Medivir AB Earnings Call TranscriptAug 19, 2021kr8.47 (-4.26%)Earnings
- Q1 2021 Medivir AB Earnings Call TranscriptApr 28, 2021kr6.55 (+1.27%)Earnings
- Q4 2020 Medivir AB Earnings Call TranscriptFeb 26, 2021kr6.88 (+0.84%)Earnings
- Medivir AB to Discuss Exclusive Licensing Agreement with IGM Biosciences for Birinapant Call TranscriptJan 12, 2021
- Q3 2020 Medivir AB Earnings Call TranscriptNov 10, 2020kr9.15 (-0.73%)Earnings
- Q2 2020 Medivir AB Earnings Call TranscriptAug 20, 2020kr9.55 (+1.57%)Earnings
- Q1 2020 Medivir AB Earnings Call TranscriptMay 05, 2020kr10.05 (-4.96%)Earnings
- Medivir AB R&D Day TranscriptMar 02, 2020
- Q4 2019 Medivir AB Earnings Call TranscriptFeb 13, 2020kr9.74 (-0.14%)Earnings
- Q3 2019 Medivir AB Earnings Call TranscriptNov 27, 2019kr14.77 (+2.09%)Earnings
- Q2 2019 Medivir AB Earnings Call TranscriptAug 28, 2019kr16.15 (-1.64%)Earnings
- Medivir AB to Discuss the Development of Phase IA Study with MIV-818 Call TranscriptJun 13, 2019
- Q1 2019 Medivir AB Earnings Call TranscriptMay 03, 2019kr11.95 (+2.19%)Earnings
Q4 2022 Medivir AB Earnings Call Transcript
Welcome everyone to our quarterly call. And operator, if we move to the next slide, slide 2, please.
So joining me in the room here at Medivir is our CFO, Magnus Christensen, who will go through the financial highlights towards the end of the call . And our CSO, Fredrik Ãberg, who will take the science section of the call in the middle. And with that, let's jump into sort of the agenda for today. So operator, if we move two slides ahead -- or actually three slides ahead to slide 5, please.
Highlights during last quarter. I think with 2022 was a year of sort of moving our lead project fostrox forward with as much speed as we possibly could. And Q4 was sort of clearly on the same focus. We are quite happy with the continued strong recruitment we've seen in the fostrox study, and we're now eagerly anticipating sort of moving to the next phase in the near term to set the recommended Phase 2 dose. And we're very encouraged with the interest we've seen in the study in terms of recruiting patients into both of the combination arms.
During Q4, we had an
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)